Shots:
- Takeda has entered into a five-year agreement with Accenture and Amazon Web Services (AWS) to support the company in moving 80% of its applications to the cloud and modernizing its research tools
- The transition of Takeda’s applications to the cloud will enable the company to remove non-differentiating technology and create a scalable architecture. The collaboration will leverage cloud and data-driven insights to accelerate drug development, increase operational agility, reduce technology costs, and develop the workforce of the future
- Additionally, the collaboration with Accenture and AWS has already helped the Takeda to use the cloud in launching a clinical trial acceleration and secure data-sharing platform for the COVID R&D Alliance in <5days. The COVID R&D Alliance is a consortium comprising 20 companies, including Takeda, Amgen, and AbbVie to study and identify the potential of COVID-19 therapies
Click here to read the full press release/ article | Ref: Takeda | Image: Enterprise Talk
The post Takeda Collaborates with Accenture and AWS to Transform into a Cloud-Based Company first appeared on PharmaShots.
